evaluation of [18f]mk-9470 as a brain tracer of cannabinoid-1 receptor in parkinson's disease and healthy subjects

Conditions: Parkinson Disease

Summary: the purpose of this study is to assess mk-9470 positron emission tomography (pet) imaging as a tool to evaluate the activity of the cb-1 receptor in the brain.

the underlying goal of this study is to assess mk-9470 pet imaging as a tool to evaluate the activity of the cb-1 receptor in the brain of parkinson's disease (pd) research participants.

Eligibility criteria:
early pd subjects inclusion criteria: * the participant is 30 years or older. * written informed consent is obtained. * participants have a diagnosis of pd (based on uk brain bank criteria) within the past 2 years. * modified hoehn and yahr stages 1-2. * no evidence of dyskinesia by history or clinical examination * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-mk-9470 injection. advanced pd subjects inclusion criteria: * the participant is 30 years or older. * written informed consent is obtained. * participants have a diagnosis of pd (based on uk brain bank criteria) of at least 5 years duration. * modified hoehn and yahr stages 1-4. * no evidence of dyskinesia by history or clinical examination * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-mk-9470 injection. subjects who have a clinical diagnosis of advanced pd with dyskinesia will be recruited for this study. epd subjects inclusion criteria: * the participant is 30 years or older. * written informed consent is obtained. * participants have a diagnosis of pd (based on uk brain bank criteria) of at least 5 years. * modified hoehn and yahr stages 1-4. * evidence of dyskinesia either by history or clinical examination * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-mk-9470 injection. pd (all stages- e-pd, apd, apd-dys)subject selection. subjects who have a clinical diagnosis of epd, apd, apd-dys will be recruited for this study. all pd subjects exclusion criteria: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness * the subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion. * the patient has evidence of unstable gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, pulmonary, or other disorder or disease. * evidence of a stroke or mass lesion in a clinically relevant area that may interfere with the imaging outcome measure * subjects with radiation exposure above acceptable levels * pregnancy healthy control subject selection: subjects who have no neurological disease will be recruited for this study. healthy control subjects inclusion criteria: * the participant is 18 years or older. * written informed consent is obtained. * negative history of neurological or psychiatric illness based on evaluation by a research physician. * for females, non-child bearing potential a negative urine or blood pregnancy test on day of \[18f\]-mk9470 injection. exclusion criteria: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * the subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion. * subjects with radiation exposure above acceptable levels * pregnancy

Keywords: parkinson disease molecular neuroimaging